Cargando…
A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia
BACKGROUND: Dyslipidemia is one of the most frequently implicated risk factors for development of atherosclerosis. This study evaluated the efficacy of amla (Emblica officinalis) extract (composed of polyphenols, triterpenoids, oils etc. as found in the fresh wild amla fruit) in patients with dyslip...
Autores principales: | Upadya, Haridas, Prabhu, S., Prasad, Aravinda, Subramanian, Deepa, Gupta, Swati, Goel, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341673/ https://www.ncbi.nlm.nih.gov/pubmed/30670010 http://dx.doi.org/10.1186/s12906-019-2430-y |
Ejemplares similares
-
A Randomized, Triple-Blind, Placebo-Controlled, Add-On Clinical Trial to Evaluate the Efficacy of Emblica officinalis in Uncontrolled Hypertension
por: Ghaffari, Samad, et al.
Publicado: (2020) -
Comparative antimicrobial activities of Emblica officinalis and Ocimum sanctum
por: Vijayalakshmi, S., et al.
Publicado: (2007) -
Attenuation of Hyperlipidemia by Medicinal Formulations of Emblica officinalis Synergized with Nanotechnological Approaches
por: Rachitha, Puttasiddaiah, et al.
Publicado: (2023) -
Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study
por: Kapoor, Mahendra Parkash, et al.
Publicado: (2019) -
Nutraceutical effects of Emblica officinalis in age-related macular degeneration
por: Nashine, Sonali, et al.
Publicado: (2019)